J&J: EU body backs Janssen's new prostate cancer drug
(CercleFinance.com) - European regulators on Friday issued a positive opinion on Janssen's apalutamide, a next generation oral drug for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
The CHMP's positive opinion is based on Phase 3 data that showed that apalutamide reduced the risk of developing distant metastasis or death compared to placebo by 72%.
The CHMP's positive opinion will now be reviewed by the European Commission.
Janssen is a unit of US biopharmaceutical giant Johnson & Johnson.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The CHMP's positive opinion is based on Phase 3 data that showed that apalutamide reduced the risk of developing distant metastasis or death compared to placebo by 72%.
The CHMP's positive opinion will now be reviewed by the European Commission.
Janssen is a unit of US biopharmaceutical giant Johnson & Johnson.
Copyright (c) 2018 CercleFinance.com. All rights reserved.